Abstract: A transfer arrangement comprising a syringe (110) having a side wall defining a cavity (116) which is sealed by plunger (114), a needle (119) being connected to a second syringe end (113), an adaptor (124) having a first adaptor end (121) connecting to the second syringe end (113), the adaptor (124) extending about the needle (119), second adaptor end (123) having a luer connector (126), and a transfer member (128) having first and second transfer member ends (131, 133) with the first transfer member end (131) being connected to the second adaptor end (123) while the second transfer member end (133) receives the neck of a vial (130).

Abstract: A system for administering a medicament includes a plurality of capsules, a capsule dispenser, and a capsule activator. Each of the capsules includes a reservoir containing a medicament and an outlet in communication with the reservoir through which the medicament exits the capsule. The capsule dispenser releasably contains the ingestible capsules and is adapted to dispense the capsules to a user in accordance with a predetermined schedule. The capsule activator activates the dispensed capsules prior to administration to the user.

Abstract: A multi lumen gastrointestinal catheter is disclosed. The multi-lumen gastrointestinal catheter has a flexible partition separating a feeding and an aspiration channel. A third smaller inflation channel is positioned within the outside exterior wall at the site of the flexible partition to avoid kinking at the inflation channel site, without need to re-enforce the weakened wall.

Abstract: A combination pacifier and storage device and method of same are provided. The device includes a pacifier having a nipple, having a distal end having a sucking portion, and a proximal end having a shank portion, and a guard that extends laterally outward from the proximal end adjacent the shank portion. The device includes a storage container including a housing having an elongated opening with arcuate top and bottom ends and oppositely orientated outwardly extending protrusions of particular shape to accommodate the sucking portion of the nipple. The device includes means for removably connecting the container to an object or body part.

Abstract: A dental restorative material including a photocurable composition that contains a polymerizable monomer component (A), an inorganic filler component (B) having an average particle size of not smaller than 0.07 ?m, and a photo polymerization initiator (C), the inorganic filler component (B) being contained in an amount of 100 to 1500 parts by mass per 100 parts by mass of the polymerizable monomer component (A), and the polymerizable monomer component (A) and the inorganic filler component (B) being so selected as to satisfy a condition (X1) represented by the following formulas (1a) and (1b): nF?0.005<nM<nF+0.005??(1a) nF+0.020<nP<nF+0.040??(1b) wherein, nM is a refractive index of the polymerizable monomer component (A) at 25° C., nP is a refractive index at 25° C. of a polymer obtained by polymerizing the polymerizable monomer component (A), and nF is a refractive index of the inorganic filler component (B) at 25° C.

Abstract: A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, a basic active ingredient, and C) from about 0.1% to about 20% by weight of at least one acidic solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.

Abstract: Methods of obtaining a carotenoid-containing composition were developed, in which degradation of carotenoids is suppressed even though extraction and purification are performed on a culture of microorganism that produces carotenoids including astaxanthin by simple steps using a lower alcohol which is a conventionally known solvent, and the compositions have high astaxanthin content and contain highly pure carotenoids and also have satisfactory crystal properties. Further addition of a simple step that promotes isomerization of astaxanthin successfully improved the carotenoid yield.

Abstract: The invention relates to a wet wipe product comprising a substrate and an emulsion. The wet wipe is sized and configured to enable a user to effectively cleanse an infant's entire body with a single wipe. The wipes are preferably made from nonwoven fabrics. The emulsion is particularly formulated to provide a mild cleansing with little or no irritation or drying to an infant's skin, hair or eyes.

Abstract: A topical composition comprising a substituted resorcinol and a solid powder having a particle size distribution width of at least 15 microns is provided. Methods of treating the skin are also provided.

Abstract: The present invention relates to inorganic powder coated with biocompatible polymer and a cosmetic composition comprising same. More particularly, the present invention relates to an organic/inorganic composite powder in which the rough surface of the inorganic powder is treated with biocompatible polymer, thereby improving dispersibility and feeling of use and to a cosmetic composition comprising said composite powder so as to achieve improved feeling of use and tight adhesion when applied to the skin.

Abstract: A particle comprising: a core, comprising an optional benefit agent; an inner shell at least partially surrounding the core, said inner shell being the water insoluble product of a polymerisation reaction to form a first polymer with a glass transition temperature above and including 70 degrees Celsius, preferably above and including 80 degrees Celsius; an outer shell at least partially surrounding said inner shell, said outer shell being the water insoluble product of a polymerisation reaction to form a second polymer with a glass transition temperature below and including 35 degrees Celsius; and a deposition aid, covalently attached to the outer shell.

Abstract: A color-changing composition for caring for and/or making up keratin materials is disclosed. The composition comprises: - a physiologically acceptable medium including at least an aqueous phase, - color-changing microcapsules, said microcapsules having a size ranging from 50 ?m to 1000 ?m, preferably from 80 ?m to 800 ?m, in particular from 100 ?m to 400 ?m, and comprising: (A) a core, having preferably a size ranging from 20 ?m to 800 ?m, comprising at least one colorant and preferably at least one binder, said colorant(s) including preferably at least one inorganic pigment preferably selected from iron oxide(s), and (B) a pressure-breakable wall layer surrounding said core, having preferably a thickness of 10 ?m to 300 ?m, comprising at least one colorant and preferably at least one binder, said colorant(s) including preferably at least titanium dioxide particles, Wherein said microcapsules includes at least 70% by weight of colorant(s), compared to the total weight of said microcapsules.

Abstract: The invention relates to a method of making an anhydrous, pigmented sunscreen composition. The method comprises first adding a hydrophobic silica to a lipid phase comprising a dispersed color pigment and an organic UV-filter and homogenizing the mixture. Next, a hydrophilic silica is added and re-homogenization is performed.

Abstract: The present invention relates especially to a composition for dyeing keratin fibres, in particular human keratin fibres such as the hair, comprising: (i) one or more fatty substances in a content ranging from 40% to 85% by weight relative to the total weight of the dye composition, (ii) one or more oxyethylenated fatty alcohols with an oxyethylene number of less than or equal to 10, and (iii) one or more nonionic surfactants of alkylpolyglucoside type, (iv) optionally one or more alkaline agents, (v) one or more direct dyes which are preferably cationic, anionic or neutral. The present invention also relates to a process for dyeing keratin fibres, comprising the application to the said fibres of an above mentioned composition, optionally in the presence of a composition comprising one or more chemical oxidizing agents; the dye composition possibly resulting from the mixing of several compositions. Finally, the invention relates to devices that are suitable for performing this process.

Abstract: The present invention relates to a cosmetic composition comprising: one or more dicarbonyl derivatives corresponding to formula (I) below, and/or derivatives thereof and/or hydrates thereof and/or salts thereof: ?in which formula (I) R?H, COOH, linear or branched C1-C6 alkyl which is optionally substituted with an OH or COOH or Br radical; phenyl or benzyl optionally substituted with an OH or COOH radical; or alternatively an indolyl radical or one or more silanes corresponding to formula (II) below and/or oligomers thereof: R1Si(OR2)z(R3)x(OH)y??(II) ?in which formula (II): R1 is a linear or branched, saturated or unsaturated, cyclic or acyclic C1-C6 hydrocarbon-based chain substituted with a group chosen from the following groups: amine NH2 or NHR (R?C1-C20 and especially C1-C6 alkyl optionally substituted with a radical comprising a silicon atom, C3-C40 cycloalkyl or C6-C30 aromatic), or with a hydroxyl group, a thiol group, an aryl or aryloxy group which is unsubstituted

Abstract: A white, color stable, sunless tanning formulation containing vanillin and dihydroxyacetone for tanning, and octyl salicylate plus octyl methoxycinnamate for color stabilization.

Abstract: An agent for dyeing and/or bleaching keratin fibers, in particular human hair, including in a cosmetic carrier (a) at least one fatty alcohol selected from the group of arachyl alcohol (eicosan-1-ol), gadoleyl alcohol ((9Z)-eicos-9-en-1-ol), arachidonic alcohol ((5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraen-1-ol), heneicosyl alcohol (heneicosan-1-ol), behenyl alcohol (docosan-1-ol), erucyl alcohol ((13Z)-docos-13-en-1-ol) and brassidyl alcohol ((13E)-docosen-1-ol), (b) at least one persulfate salt selected from the group of ammonium persulfate, potassium persulfate and sodium persulfate, and (c) at least one glyceryl fatty acid ester of general formula (I), in which R1, R2 and R3 independently of one another stand for a hydrogen atom or a grouping of formula (II), in which R4 stands for an unbranched or branched, saturated or unsaturated C11-C28 alkyl group, with the proviso that at least one and at most two of the radicals selected from R1, R2 and R3 stand for a grouping of formula (II).

Abstract: Useful compositions are described herein that comprise a solvent base comprising at least one non-aqueous solvent; at least one sunscreen active ingredient that is a UV blocker and/or a UV absorber; and a polymer reaction product of a random polymerization of at least one organic diol, at least one polycarboxylic acid and at least one polyol having at least three functional groups. Such compositions are particularly useful in clear compositions including sunscreens for personal care including spray sunscreen formulations that are applied to and effective on wet skin, hair or nails.

Abstract: A skin engaging shaving aid member suitable for use in a shaving device, said skin engaging shaving aid member comprising a thermally resilient sensate such as N-substituted menthanecarboxamide and a TRPA1 receptor inhibitor.

Abstract: Stable whiteness is provided by adding stabilizers to a topical anti-aging, anti-oxidant sunscreen or skin care formulation containing Tinosorb S and other optional ingredients, including CoQ10. The formulation will not stain clothing or other fabrics.

Abstract: An agent for the oxidative dyeing of keratin fibers, in particular human hair, includes in a cosmetic carrier (a) at least one first alkyl glucoside of formula (I) set forth herein, in which R1 is an unbranched or branched, saturated or unsaturated C20-C28 alkyl group and n is an integer from 1 to 10, (b) at least one second alkyl glucoside of formula (II) set forth herein, in which R2 is an unbranched or branched, saturated or unsaturated C8-C18 alkyl group and m is an integer from 1 to 10, (c) at least one oxidation dye precursor of the developer type, and d) at least one oxidation dye precursor of the coupler type.

Abstract: Provided is hyaluronic acid gel suitable for cosmetic and medical field. The hyaluronic acid gel contains hyaluronic acid, polycarboxylic acid or oxycarbonic acid, and polyhydric alcohol. The hyaluronic acid gel is produced by drying moisture of an aqueous solution in which the hyaluronic acid, the polycarboxylic acid, and the polyhydric alcohol are uniformly dissolved to be an intended form.

Abstract: The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favourable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).

Abstract: The present invention provides a lubricating resin composition for personal care, wherein the composition comprises 100 parts by mass of a thermoplastic elastomer having durometer A hardness (HDA) of 10 to 40, 10 to 40 parts by mass of a water-soluble polyethylene oxide, and 20 to 60 parts by mass of a water-absorbent modified polyalkylene oxide, and wherein the composition not only maintains its superior lubricity and roughness-resistant property under a wet condition even in repeated use thereof, but also represents a low swelling ratio and no slimy feeling under a wet condition.

Abstract: [Problem] To provide a makeup base for skin that is applied to the skin before applying foundation and the like. The makeup base is not smeared or removed by sweat or cold water, but, when rubbed with warm water, it can be easily removed from the skin together with the makeup cosmetic without using a cleanser such as a makeup remover or a face wash. [Solution] A makeup base for skin applied to the skin before applying a makeup cosmetic for skin, the makeup base comprising a water-containing aqueous phase as a continuous phase and containing: (a) a vinyl acetate polymer, (b) polyhydric alcohol, and (c) a hydrophilic nonionic surfactant, wherein (a) the vinyl acetate polymer is 0.5 to 7 mass % in the makeup base and is dispersed as particles in the aqueous phase, (b) the polyhydric alcohol is 0.5 to 5.5 parts by mass relative to 1 part by mass of (a) the vinyl acetate polymer, and (c) the hydrophilic nonionic surfactant is 1 to 5 mass % in the makeup base.

Abstract: Embodiments presented herein relate to acrylamide derivatives and uses thereof. Examples of such derivatives include acrylamide pyranose and other acrylamides that have other carbohydrate or 5 or 6 membered rings attached thereto. The compositions can be used for a variety of purposes, e.g., cosmetics, construction, scaffold materials, hydrogels, food additives, baby diapers, tubing sieves, etc.

Abstract: Provided is a cosmetic sheet formed from nanofiber that is obtained by preparing a spinning solution that is formed by dissolving a water-soluble polymer material together with a functional material in a solvent of water or alcohol, and electrospinning the spinning solution wherein the nanofiber has a controlled dissolution velocity and has fine pores. The water-soluble nanofiber layer can control a dissolution velocity by moisture or mist through crosslinking. The attached cosmetic sheet is a soluble melt-type such that the cosmetic sheet is naturally melted and absorbed into the skin, thereby being used in everyday life without having to be removed separately, and having excellent thin and adhesive properties.

Abstract: A liquid cleansing composition comprising a cleansing effective amount of surfactant and an alkoxylated alkyl ether having 5 to 20 alkoxy moieties and a C3 to C12 alkyl. The alkoxylated alkyl ether can be PPG-14 butyl ether.

Abstract: Dental bleaching compositions include a dental bleaching agent, a generally linear high molecular weight (e.g., greater than about 500,000) polyvinyl pyrrolidone (PVP) and/or polyethylene oxide (PEO) tissue adhesion agent included in amount that imparts a high level of adhesiveness, a rheology-modifying agent such as fumed silica or fumed alumina that reduces or eliminates stringiness otherwise caused by the high molecular weight PVP and/or PEO, and a solvent or carrier. Dental bleaching compositions may include carboxypolymethylene instead of or in addition to PVP and/or PEO, wherein the fumed silica or fumed alumina increases long-term rheological stability even in the presence of a high concentration of dental bleaching agent. Dental treatment devices including a barrier layer and a quantity of the dental bleaching composition positioned adjacent to the barrier layer.

Abstract: A surface treatment agent or a powder treatment agent comprising a co-modified organopolysiloxane is disclosed. The co-modified organopolysiloxane is represented by the general formula: R1aR2bQcSiO(4-a-b-c)/2. The co-modified organopolysiloxane has a number average molecular weight of less than 4500 and includes a long-chain alkyl group and a polyoxyalkylene group in the molecule.

Abstract: Hair treatment agents include alkoxylated silicones and/or dimethicones and/or cyclomethicones and/or dimethiconols and/or amino functional silicones and silicones that include sugar structures.

Abstract: Hair treatment agents include selected amino acids and/or selected oligopeptides and/or selected cationic protein hydrolysates and silicones that include sugar structures.

Abstract: Dispersions of an encapsulated material by a polymeric membrane in a medium are disclosed. Such dispersions are useful in topical compositions including cosmetics and sunscreens.

Abstract: The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising: an aqueous phase, particles comprising at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point greater than or equal to 60° C., the hard wax(es) being present at a total content greater than or equal to 10% by weight relative to the total weight of the composition, at least one particular emulsifying system capable of dispersing at least the hard wax(es). The present invention also relates to a method for coating keratin fibres, to a method for preparing a cosmetic composition for coating keratin fibres, to a cosmetic composition for coating keratin fibres which is obtained by means of said production method, and also to a particular use.

Abstract: The invention relates to a method of reducing skin pigmentation. The method includes the steps of providing an H3 antagonist configured to prevent histamine from connecting to an H3 receptor, thereby preventing the H3 receptor from initiating melanin production; adding the H3 antagonist to a cosmetic product; and applying the cosmetic product to a user's skin.

Abstract: Substance mixtures are proposed, comprising (a) terpenes, (b) propane-1,3-diol, and optionally (c) active substances selected from the group consisting of (c1) rebaudiosides or plant extracts comprising them, (c2) steviosides or plant extracts comprising them, (c3) monatin, (c4) naringin, (c5) chalcones and hydrochalcones, (c6) mogrosides or plant extracts comprising them, (c7) rubusosides or plant extracts comprising them, and (c8) glycyrrhizic acid or plant extracts comprising it.

Abstract: Compositions for treating keratinic fibers, in particular human hair, which in addition to the conditioning properties and the luster and feel of keratinic fibers, in particular human hair, have an improved effect with regard to the removal of dandruff on the keratinic fibers.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for Parkinson's disease comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising levodopa, sinemet, atropine sulfate, scopolamine, dopamine agonist, bromocriptine mesylate, selegiline, carbidopa, entacapone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. Therefore, the present invention can provide a treatment for Parkinson's disease that combines the convenience of taking the medicine while also having better curative effects on the user.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for Alzheimer's disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, memantine hydrochloride, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for heart disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising acetylsalicylic acid, clopidogrel, propranolol, atenolol, nadolol, carvedilol, nifedipine, diltiazem, verapamil, isosorbide dinitrate, nicorandil, nitroglycerin, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for arthritis and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising indomethacin, flurbiprofen, celecoxib, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for gout and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising colchicine, allopurinol, probenecid, sulfinpyrazone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: This invention is directed to a superior adhesive for oral adhering discs or troches. The adhesive is at least 80% acacia gum mixed with calcium carbonate so that, as the acacia gum is combined with water, it does not yield a pH lower than 5.5. The preferred ratio of acacia gum to calcium carbonate is within the range 15:1 to 50:1.

Abstract: An oromucosal solution comprising about 1-8% (w/v) apomorphine or a pharmaceutical acceptable salt thereof solubilised in a non-aqueous carrier containing at least about 50% (v/v) of propylene glycol. A small volume (25-250 ?L) of said solution containing about 1-12 mg apomorphine may be administered upon demand to treat motor fluctuations during off periods in patients suffering from Parkinson's disease. The solution may also be used for the treatment of sexual dysfunction.

Abstract: The present invention relates to an effervescent tablet, which upon dissolution in water provides a solution useful as a mouth wash or oral rinse for the prevention or treatment of inflammatory processes of the soft tissues of the mouth, throat and oral cavity.

Abstract: An object of the present invention is to provide a lung-specific therapeutic agent that can be intravenously administered. The present invention provides a lung-specific therapeutic agent characterized by containing sustained-release microspheres that contain a pharmaceutical compound and being intravenously administered.

Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.

Abstract: Biodegradable intraocular and intraarticular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye or joint for an extended period of time are described. The drug delivery systems may be in the form of an extruded implant and may be used to treat one or more medical and ocular conditions, such as post-operative pain and inflammation following an ocular surgery such as cataract surgery.

Abstract: The invention relates to a product for oral delivery of nicotine containing a core comprising a powder of at least one free nicotine salt, at least one pH adjusting agent and at least one filler, and a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said product upon contact with purified water gives a pH of at least 6. The invention also relates to a method to manufacture such a product.